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SignallingThe cellular consequences of deﬁciencies of the mitochondrial OXPHOS system include a variety of direct and
secondary changes in metabolite homeostasis, such as ROS, Ca2+, ADP/ATP, and NAD/NADH. The adaptive
responses to these changes include the transcriptional responses of nuclear and mitochondrial genes that are
mediated by these metabolites, control of the mitochondria permeability transition pore, and a great variety
of secondary signalling elements. Among the transcriptional responses reported over more than a decade
using material harboring mtDNA mutations, deletions, or depletions, nuclear and mitochondrial DNA
OXPHOS genes have mostly been up-regulated. However, it is evident from the limited data in a variety of
disease models that expression responses are highly diverse and inconsistent. In this article, the mechanisms
and controlling elements of these transcriptional responses are reviewed. In addition, the elements that need
to be evaluated, in order to gain an improved perspective of the manner in which OXPHOS genes respond and
impact on mitochondrial disease expression, are highlighted.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The mitochondrial oxidative phosphorylation (OXPHOS) system,
which produces the majority of cellular energy in the form of ATP, is
controlled on the genetic level by two distinct genomes: the circular
mitochondrial genome (mtDNA) and the nuclear genome. The circular
mitochondrial genome of ∼16.6 kb encodes thirteen structural
subunits of complex I, III, IV, and V 22 tRNA and two ribosomal RNA
genes used for RNA translation [1]. The nuclear genome encodes the
additional genes required for mtDNA maintenance, replication,
transcription, translation, post-translational modiﬁcation, transport,
and assembly exclusively. In addition, the nuclear genome controls all
other aspects of mitochondrial biosynthesis and function. Nuclear–
mitochondrial communication is a highly complex process dominated
by the nucleus [2].
A deﬁciency in mitochondrial function is caused by a dysfunction
of one (or more) of hundreds of nuclear- or mitochondrial-encoded
proteins. Over the past two decades, it has become clear that the
interplay between the mitochondrion and nuclear genome affects
mitochondrial disease expression, as evident in diseases that result
frommutations in genes involved in themtDNA replicationmachinery
and in nucleotide metabolism. This impacts qualitatively and/or
quantitatively on mtDNA, such as progressive external ophthalmo-
plegia (PEO), mitochondrial DNA depletion syndrome, and mitochon-
drial neurogastrointestinal encephalomyopathy (MNGIE) [3].27 18 299 2477.
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ll rights reserved.Mitochondrial interplay with the nuclear genome is also evident in
the disorders of nuclear- and mtDNA-encoded subunits of the
OXPHOS complexes. Primary deﬁciencies of the OXPHOS system
impact directly onmitochondrial function and result in several disease
phenotypes [4]. With recent advances in systems biology for
investigating gene expression and function, key aspects of nuclear–
mitochondrial communication in these deﬁciencies have been
revealed. As with these deﬁciencies in which the mtDNA replication
machinery has been primarily compromised, differential expression of
mtDNA and nuclear OXPHOS genes occurs in cells with mtDNA or
nuclear mutations of structural subunits of the OXPHOS system.
Differential expression of OXPHOS and related genes has a signiﬁcant
impact on disease expression because of the importance of these
genes in energy metabolism, which is compromised in these
disorders. This article highlights these observations and investigates
the underlying cellular mechanisms that control mitochondrial and
nuclear OXPHOS gene expression.
2. Cellular biochemical consequences of OXPHOS deﬁciencies
Oxidative phosphorylation and deﬁciencies thereof involve and
modulate a great number of cellular functions and metabolic
processes upstream and downstream of the ﬁve enzyme complexes.
Moreover, in considering the effect of OXPHOS deﬁciencies, it is
essential to recognize that deﬁciencies of the individual enzyme
complexes may result in varied biochemical responses. This is evident
from existing (but limited) reports of biochemical and gene expres-
sion responses to various deﬁciencies of OXPHOS as discussed in this
article.
Table 1
Summarized ﬁndings of OXPHOS and other gene expression investigations of human mitochondrial disorders.
Tissue Phenotype/deﬁciency
(genotype)
Technique nDNA expression mtDNA expression Reference
Skeletal muscle MERRF (mtDNA 8344),
MELAS (mtDNA 3243),
KSS (mtDNA del)
mRNA, Northern blot •ATPsynβ, ANT1 ↑, GAPDH ↓
(MELAS, MERRF)
•Transcripts ↑ [32]
•ATPsynβ, ANT, GAPDH ↓ (KSS) •Processing (light/heavy
strand transcript ratios) ↓
Skeletal muscle
(cultured)
CIII deﬁciency (mtDNA cytb),
MELAS (mtDNA 3243, CI+ IV),
MELAS+CM (mtDNA 3243,
CI+ IV), CPEO+PM
(mtDNA del, CI+ IV), KSS
(mtDNA del, CI+IV),
CII deﬁciency (nuclear),
CIV deﬁciency (nuclear)
mRNA, Northern blot •ATPsynβ, GAPDH ↑ (MELAS,
MELAS+CM, CPEO,
CII deﬁciency)
•Transcripts ↑
(excl. CIII deﬁciency)
[34]
•ATPsynβ, GAPDH ↓
(CIII deﬁciency)
•Transcripts ↓
(CIII deﬁciency)
•mtDNA/nDNA ↓
Skeletal muscle, heart
muscle, liver, kidney,
brain
LHON (mtDNA 11,778),
NARP (mtDNA 8993),
MELAS (mtDNA 3243,
CI+IV), MERRF (mtDNA
8344/9344), MDMD
(mtDNA del/dup), CPEO
(mtDNA del), FSHMD
(nuclear)
mRNA, Northern blot •↓ATPsynβ, ANT1/2 ↑
(excl. MDMD)
•Transcripts ↑ [33]
•Glycolytic/bioenergetic
genes generally ↑
•mtDNA/nDNA ↓
(most tissues for MELAS)
Skeletal muscle
(cultured)
MELAS (mtDNA 3243),
KSS (mtDNA del)
mRNA, Northern blot,
competitive RT-PCR
•ATPsynβ ↓ (MELAS) •ND2 ↑ [35]
•mtDNA/nDNA ↓ (MELAS)
•mtDNA/nDNA ↑ (KSS)
Fibroblasts mtDNA depletion
(CII+ III, CIV), RhoO
(EtBr induced, CII+ III, CIV)
Protein, Western blot •COXVIc absent Absent due to defect [36]
•COXVI, COXVa, SD30, SD70 ↓
Skeletal muscle Myopathy (mtDNA del),
PEO (mtDNA 3243),
MELAS (mtDNA 3243)
(for all groups, varying
deﬁciencies of combined
CI, CI+III, CII+III,
and CIV are reported)
mRNA, microarray
(Affymetrix HG U133A,
22 283 oligonucleotide
targets)
•OXPHOS structural genes ↑
(mtDNA del)
Not reported [38]
•Genes involved in urea
cycle/arginine catabolism ↑
•CDKN1A, -1C (cell cycle G1
arrest, DNA repair mediators),
and other cell cycle regulators ↑
•CFLAR (anti-apoptosis) ↑
•PEX6 (peroxisomal biogenesis),
MAOA (neurotransmitter
catabolism) ↓
•RNA Pol II regulation ↑
(MELAS) ↓ (PEO)
•Neurobiological structures,
fatty acid oxidation,
detoxiﬁcation of H2O2,
cell signalling ↓ (PEO)
Cybrids LHON (mtDNA 11778 and 3460),
mtDNA depletion
mRNA, microarray (Affymetrix
U95Av2, 12 599 oligonucleotide
targets)
•Respiratory chain genes,
TCA and other aerobic
bioenergetic pathways,
Pol II promoter transcription
and regulation, anti-apoptosis
mostly ↑ (mtDNA depletion)
Not reported [42]
•Aldose reductase (aldehyde
reduction), integral membrane
protein 2B (anti-apoptotic),
H2A histone O (chromosome
organization/biogenesis)
↑ (LHON cell line shared)
•Scaffold protein TUBA
(dynamin/actin regulatory),
MTHFD (THF/purine metabolism),
sialyltransferase 1 (sialic acid
transfer/cell surface antigens/
determinants), Raf1 (signal
transduction/proliferation/
differentiation/apoptosis),
lipin 1, immunoglobin
super family member 3 ↓
(LHON cell line shared)
Lymphoblasts mtDNA depletion mRNA, microarray
(Affymetrix HG U133A,
22 283 oligonucleotide
targets)
•Lipid, amino acid metabolism,
bioenergetics and transport,
intracellular homeostasis,
DNA/RNA binding, transcription,
translation, redox balance,
cell cycle control, growth arrest,
signalling, apoptosis, DNA damage
and oxidative stress protection ↑
Absent due to defect [40]
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Table 1 (continued)
Tissue Phenotype/deﬁciency
(genotype)
Technique nDNA expression mtDNA expression Reference
143B cells
(osteosarcoma)
mtDNA depletion Protein, 2-DE/MS •Respiratory chain complexes
(excl. CII and CV) ↓ (not uniformly)
Absent due to defect [43]
•Mitochondrial translation apparatus ↓
•Mitochondrial transport systems ↓
•Catabolic energy metabolism ↓
•Hax-1 (anti-apoptotic), Smac protein
(pro-apoptotic), rhodanese,
hydroxysteroid dehydrogenase ↓
Fibroblasts CV deﬁciency (mtDNA 9205
and nuclear uncharacterized)
mRNA, microarray (custom-made,
1632 oligonucleotide targets)
•OXPHOS structural genes for complex
IV and V, cell growth, differentiation
and transduction ↓ (CV nDNA defects)
•MTATP6, MTATP8,
MTCOX2 ↓
(CV mtDNA 9205)
[41]
•Cell cycle regulation, Krebs cycle
and gluconeogenesis, mitochondrial
transcription regulation (TFAM, TFB1M),
CytC, NFκB (apoptosis) ↓
(CV mtDNA 9205)
•ND1, ND2, ND4, ND4L ↑
(CV nDNA defects)
•Branched chain amino acid
and fatty acid oxidation,
complex I structural
genes and apoptosis ↑
(CV nDNA defects)
Fibroblasts
(differentially cultured)
CI deﬁciencies (nuclear): LLD
(NDUFS4, NDUFS7, NDUFS8),
HCE (NDUFS2), HPEM (NFUFV1)
mRNA, microarray
(custom-made, 618 cDNA targets)
•Metallothioneins (ROS scavenging,
heavy metal regulation), ATP1G1,
heat shock proteins ↑
•Transcripts ↓
(selected cell lines)
[37]
•Pro-apoptotic protein (BNIP3),
pyruvate dehydrogenase
de-activation (PDK1) ↓
Respiratory chain enzyme deﬁciencies are shown in italics where reported. The following abbreviations are used: LHON (Leber's hereditary optic neuropathy); NARP (neurogenic
muscle weakness, ataxia, and retinitis pigmentosa); CPEO (chronic progressive external ophthalmoplegia); KSS (Kearns–Sayre syndrome); MELAS (mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes); MERRF (myoclonic epilepsy and ragged red ﬁbers); MDMD (maternally transmitted diabetes mellitus and
deafness); FSHMD (facio-scapulohumeral muscular dystrophy); LLD (Leigh-like disease); HCE (hypertrophic cardiomyopathy and encephalomyopathy); HPEM (highly progressive
encephalomyopathy); 2-DE/MS (Two-dimensional electrophoresis/mass spectrometry).
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OXPHOS deﬁciencies is the production of superoxide. Mitochondrial
superoxide production can originate from the ineffective transfer of
electrons through the various subunits of the electron transport chain
(ETC; complexes I–IV) and the ineffective transfer of carriers
(ubiquinone, cytochrome c) through the inner mitochondrial mem-
brane. This can lead to the accumulation of electrons and excessive
leaking to oxygen to produce reactive oxygen species (ROS),
particularly when there is an increased supply of reducing equivalents
to the ETC. Complex I (at the bound ﬂavine on the matrix side) and
complex III (at the ubiquinol oxidation side) are generally regarded as
the main sources of superoxide radicals originating from the ETC [5,6].
The percentage of oxygen converted in this way to ROS under steady
state conditions is considered to be much less than the previously
estimated 1 to 2% [7] and, in case of respiratory chain deﬁciencies,
would quantitatively be dependent on the amount of electron transfer
through the chain and the site of a deﬁciency within the chain. In fact,
a signiﬁcant part of mitochondrial superoxide production may also
originate from the tricarboxylic acid cycle enzyme, α-ketoglutarate
dehydrogenase [8], and through a deﬁciency of the complex II subunit
SdhB [9]. Superoxide can result in the generation of other ROS and
nitrogen species (RNS), if not dismutated by superoxide dismutases
on either side of the mitochondrial inner membrane (Mn and Cu/Zn)
or by the radical scavenging effects of antioxidants (vitamins E and C),
metallothioneins, or quinone reductase [10,11]. Hydrogen peroxide,
which is formed by SOD, can be converted to water by catalase and
glutathione peroxidase but can alternatively be converted to hydroxyl
radicals bymeans of the Fenton reaction. The damaging effects of ROS,
RNS, and particularly hydroxyl radicals on macromolecules have been
extensively documented [12,13] and, through oxidation of these
molecules, have been shown to have a direct impact on the viability of
genetic and functional molecules inside the mitochondrion and
elsewhere in the cell. However, ROS and RNS also act as key
messengers in signalling mechanisms that lead to the induction of
genes often involved in maintenance and restoration of the cellularredox balance [14,15]. They can also act more directly by altering
protein function, such as the activation of uncoupling proteins in
brown adipose tissue and the subsequent shift from mitochondrial
coupling towards thermogenesis [16].
Abundant evidence of increased superoxide production in OXPHOS
deﬁciencies exists. However, in several reports increased superoxide
production is not detected, or an increased superoxide level has no
detectable effect on parameters associated with oxidative damage or
changes in metabolic homeostasis. Moreover, the origin of superoxide
production is not clearly established; for example, ROS production is
reported to occur in cell lines harboringmtDNAmutations [17], as well
as nuclear mutations of complex I [18,19]. However, ROS production
was not detected in a pathogenic mutation of the NDUFS4 subunit of
complex I [20] or in HeLa cells containing no mtDNA (ρ°) [21]. ROS
production in OXPHOS deﬁciencies is therefore not a generalized
occurrence and depends on several factors, including the position and
severity of the dysfunction, the source of production, and the
mechanisms that protect the cell against its possible harmful effects
[19,22–24].
Deﬁciencies of OXPHOS also result in other immediate and
downstreammetabolic, structural, and functional effects. These effects
are closely associated with mitochondrial dysfunction, and are brieﬂy
described here. The nicotinamide dinucleotide (NAD) redox balance,
which is converted to the reduced state in OXPHOS deﬁciencies, is a
fundamental mediator of several biological processes, such as energy
metabolism, calcium homeostasis, cellular redox balance, immunolo-
gical function, and gene expression [25,26]. Not surprisingly, ATP
production, and subsequently ATP/ADP homeostasis, is disturbed in
OXPHOS deﬁciencies [7]. Cellular calcium handling also becomes
disturbed during an increased oxidative state, with an inﬂux of Ca2+
into the cytoplasm, nucleus, and mitochondria [27]. This has an effect
on cellular signalling events, where Ca2+ is often a keymessenger, and
more speciﬁcally mitochondrial Ca2+ loading, which is compounded
by ROS, opens the mitochondrial transition pore, disrupts the inner
membrane potential (ΔΨ), and increases cell death through apoptosis
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itself and the subsequent reduced supply of ATP to Ca2+-ATPases leads
to reduced cellular Ca2+ stores [30].
The varied biochemical changes that occur in cases of OXPHOS
deﬁciencies have a direct effect on cellular functions. Yet, they are also
key underlying mediators of the (retrograde) communication
between the mitochondrion and the nucleus, which results in speciﬁc
gene expression of both nuclear and mitochondrial genomes.
3. Differential expression of mitochondrial and nuclear genes in
human OXPHOS deﬁciencies
The biochemical and structural changes that occur because of
deﬁciencies of the OXPHOS system involve the nuclear and mitochon-
drial genomes. Differential expression of nuclear and mitochondrial
genes has been reported for various in vivo and in vitro OXPHOS
deﬁciency models. Initial reports using targeted investigations of RNA
and protein expression have revealed the interaction between the
nuclear and mitochondrial genome. However, the development of
system biology tools over the past decade has rapidly expanded the
number of cellular processes that are affected when a deﬁciency of the
OXPHOS system occurs. In addition, these tools have shown that
energy metabolism plays a major role in several related diseases that
are not discussed in this article [31]. Table 1 summarizes the main
ﬁndings of several studies investigating gene expression in the
presence of mitochondrial disorders and highlights the expression
of nuclear andmitochondrial OXPHOS and related genes. The diversity
of the disease models used is evident; thus, except for perhaps the
data on muscle in patients harboring common mtDNA mutations and
deletions, these proﬁles cannot be directly compared with conﬁdence.
Several factors that greatly affect gene expression are signiﬁcantly
different among these reports, including the type of cell lines/tissues,
phenotypes, mutations, experimental designs, and genetic back-
ground. In addition, key information on OXPHOS enzyme activities,
which is necessary for making a comparison based on enzyme
deﬁciencies, is mostly not present or inconclusive.
Initial investigations of the expression of targeted nuclear- and
mitochondrial-encoded genes were conducted on the tissues of
patients with mitochondrial DNA mutations, deletions, or depletion
phenotypes [32–35]. Expression of nuclear genes involved in mito-
chondrial (ATPsynβ and ANT1/2) and glycolytic bioenergetics was
often increased in muscle. However, many exceptions were observed,
which included most of the various phenotypes and mutation types
where expression of these genes was either decreased or similar to the
controls [32–35]. Marusich et al. report decreased expression of
nuclear genes encoding four OXPHOS subunits—COXVI, COXVa, SD30,
and SD70—in mtDNA depleted ﬁbroblasts [36]. In addition, mitochon-
drial gene transcripts were generally found to be increased in these
patients, although exceptions in a CIII deﬁciency [34] and aMELAS and
KSS patient have been reported [35]. Interestingly, among the cases of
mtDNA mutations or deletions that mostly had a complex I and
complex IV deﬁciency, a similar expression proﬁle also occurred in a
patient with complex II deﬁciency [34]. With the one exception of a
KSS patient [35], mtDNA/nDNA ratios were generally found to be
decreased [33–35], and reduced processing (light/heavy strand) of
mtDNA transcripts was observed [32].
It was proposed from these early observations that the general
increased expression of selected genes involved in ATP synthesis was
due to a compensatory mechanism that increases transcription of
genes involved in energy production. It was further suggested that this
increased transcription only occurs when a certain threshold of
reduced energy production has been reached [32,33]. This was
evident from the study by Heddi et al., in which expression levels in
different tissues of a patient identiﬁed with a MELAS mutation were
measured [33]. They found increased expression of all selected nDNA-
encoded genes involved in OXPHOS and the glycolysis pathway in alltissues. All tissues with more than 88% mutant mtDNA showed
increased mtDNA transcripts, while kidney tissue with only 73%
mutant mtDNA showed decreased transcripts of cyt b, ND5/6, COI,
and COII; increased tRNA-Ser and -Asp; and unchanged 12S rRNA
levels.
A more detailed overview of expression proﬁles in patients with
OXPHOS deﬁciencies was obtained in recent times using micro-arrays
[37–42]. For example, the differential expression of several genes in
the muscle of patients with common mitochondrial DNA mutations
(A3243G MELAS/PEO and 4977 bp deletion) that lead to varied
combined deﬁciencies of OXPHOS enzymes, excluding complex II, are
reported [38]. Many genes showed induced expression in all patients
in the form of urea cycle/arginine metabolism; anti-apoptotic factor;
CFLAR; and selected cell cycle regulators, including cyclin-dependent
kinase inhibitor (CDKN), which is involved in G1 arrest and DNA
repair. Only a few genes showed decreased expression in all patients.
Signiﬁcantly, it was shown that some geneswere differently expressed
in the MELAS and PEO patient subsets, which contained the same
mutation but had varied levels of combined enzyme deﬁciencies, even
within phenotype groups. These differently expressed genes include
those involved in RNA polymerase II regulation, which were increased
in the MELAS subset but decreased in the PEO subset, and genes
involved in fatty acid oxidation, hydrogen peroxide detoxiﬁcation, cell
signalling, and the development of neurobiological structures.
Increased expression of nuclear encoded OXPHOS genes were
observed only in the mtDNA macro-deletion subset of patients, and
it is striking to note that the enzyme deﬁciencies within this patient
group were varied but similar to the other phenotypes. Although this
is contrary to initial reports on similar patient tissues [32–34] inwhich
general increased expression is reported for one nuclear OXPHOS
gene, ATPsynβ, differential expression of OXPHOS genes was not
associated tomtDNAmutations (LHON 11778 and 3460) in cybrids but
rather strongly associated tomtDNA depletion [42]. In Danielson et al.,
the depletion process of mtDNA had a signiﬁcant effect on genes
involved in mitochondrial bioenergetics pathways, which included
increased expression of seventeen genes involved in OXPHOS [42].
Supporting observations have been reported in mtDNA depleted (ρ°)
lymphoblasts [40]. In 143B (osteosarcoma) cells, however, conﬂicting
reports indicate either the decreased expression [43] or unaffected
expression [44] of OXPHOS genes inmtDNA depleted cells. Differential
expression of nuclear encoded structural OXPHOS genes is mostly not
reported in micro-array data sets (from which it is assumed they are
unaffected) in which deﬁciencies originate from either mitochondrial
or nuclear mutations and appear to be exclusively associated with
mtDNA depletion. In fact, Cízková et al. report a decreased expression
of complex IV and V genes in ﬁbroblasts of isolated complex V
deﬁcient patients harboring nuclear mutations [41]. In Chevallet et al.,
differential levels of decreased respiratory complex subunits, transla-
tion apparatus (particularly mitochondria ribosomal proteins), and
ion and protein import systems, such as membrane proteins, were
found in 143B ρ° cells when compared to wild-type cells [43]. The
decreased levels of subunits of respiratory complexes were not
signiﬁcant or uniform (CII and CV subunits remained unchanged),
indicating that some stable sub-complexes can survive in ρ°
mitochondria. It was suggested that this is because some sub-
complexes have other unknown functions or because they are
important for mitochondrial stability, or else because of unregulated
coordinated nuclear transcription.
Similarities in the differential gene expression of mtDNA depleted
(ρ°) lymphoblasts [40] and cybrids [42] have been reported. Increased
expression of the genes involved inmitochondrial energymetabolism,
including TCA cycle and ETC, in addition to transcription regulation
occurred in these cell lines. Dissimilarities were observed in the
induction of anti-apoptotic factors in cybrids, while several pro-
apoptotic factors were increased in lymphoblasts. This again demon-
strates the cell-speciﬁc regulation of gene expression, and indicates
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the cell type can direct apoptosis induction [45].
Comprehensive expression proﬁles of nuclear encoded OXPHOS
deﬁciencies of the OXPHOS system are limited, including only a
comparison of expression under deﬁned energy source changes in
isolated complex I deﬁcient ﬁbroblasts [37] and, recently, in nuclear
encoded complex V deﬁciency [41]. In both these cases as well,
similarities and marked variations of expression proﬁles were
detected, even in patients that harbored the same mutation.
Furthermore, no correlation could be made with the levels of enzyme
deﬁciency. Signiﬁcant increased expression of the ROS scavenging and
metal regulating family of proteins (metallothioneins) and decreased
expression of pro-apoptotic protein (BNIP3) and pyruvate dehydro-
genase de-activation protein (PDK1) occurred in complex I deﬁcient
cells when culture conditions were changed from glucose to galactose,
in order to challenge oxidative energy production [37]. In selected
patients, and notably in the patient with the most severe deﬁciency,
signiﬁcantly decreased expression of mtDNA transcripts occurred.
However, increased expression of mtDNA transcripts was detected in
nuclear encoded complex V deﬁcient ﬁbroblasts [41]. This was
accompanied by increased expression of fatty acid catabolism,
complex I structural genes, and apoptosis, while decreased expression
of nuclear complex IV and V structural genes, cell growth, differentia-
tion, and transduction were reported. In the same report, and in
contrast to the reports referring to mitochondrial DNA mutations and
deletions mentioned previously, mtDNA mutations of complex V
resulted in decreased expression of genes of the TCA cycle, cell cycle
regulation, mitochondrial transcription, and apoptosis.
It is thus evident from studies of differential expression in
mitochondrial disorders that there is great variation in the expression
of both nuclear and mitochondrial genes. For OXPHOS genes in
particular, the variation in expression also occurs under steady state
levels over a more than two-fold range between various tissues and
cells and of different sources [44]. This is an important observation, as
the varying levels of steady state expression are similar to what is
often regarded as ‘differential expression’ when pathology is inves-
tigated. In the limited published data of a highly varied group of
patient cell lines and enzyme deﬁciencies, induced expression of
genes involved in energy metabolism occurs in most of the cases.
However, the diversity of expression of these genes and apparent lack
of correlation with the type and level of OXPHOS enzyme deﬁciency
strongly underscores the signiﬁcant inﬂuence of genetic make-up in
cellular response.
4. Regulation of nuclear OXPHOS gene expression
Nuclear gene expression of OXPHOS and other genes involved in
mitochondrial function and protection is controlled by retrograde
(mitochondria-to-nucleus) signalling mechanisms. These signalling
pathways are modulated in part by metabolites controlled by the
mitochondrion, including Ca2+, ROS, and ATP. The interplay between
these metabolites in the mitochondrion and their control of the
mitochondrial permeability transition pore has previously been
reported on [29; 30; 44; 47]. Much less is known, however, about
the downstream signalling mechanisms of these retrograde effectors
in eukaryotes. Calcium-mediated signalling can involve one ormore of
several pathways, including activation of calcineurin (an activator of
NFAT and NFκB), Ca2+-dependent PKC, JNK/MAPK, and CaMK IV (and
CREB) pathways [46,48]. An extensive number of enzymes and other
proteins involved in cell signalling are targets of ROS or are sensitive to
redox state changes. These include phospholipases A2, -C and -D;
tyrosine phosphatases; guanylyl cyclase; ion and calcium channels;
AP-1 and NFκB transcription factors; several protein kinases; HIF-1α;
and the JNK/MAPK pathways that activate, amongst other, nuclear
factor-erythroid 2 p45 subunit-related factors 1 and 2 (Nrf1 and -2),
which have similar but distinct functions in the expression ofantioxidant defense and xenobiotic-metabolizing genes containing
one or more antioxidant responsive elements (ARE) [9,15,23,49].
Evidence also indicates that increased oxidative stress is involved in
the expression of the nuclear respiratory factor-1 (NRF-1, unrelated to
Nrf), which is a key transcription factor in the expression of several
genes involved in mitochondrial function [50,51]. NRF-1 activation
and increased cytochrome c expression have also been associated
with the activation of the nuclear-localized, AMP-activated protein
kinase (AMPK) as a result of, among others, decreased ATP/AMP ratio
[52].
Gene expression data from several of the studies presented in
Table 1 support the possibility that regulation of OXPHOS genes may
be co-regulated. Recently, Van Waveren and Moraes have shown that
not only OXPHOS genes are co-expressed, but also that subunits
within OXPHOS complexes are co-expressed [53]. This co-expression
is statistically associated with a selection of cis-acting elements in
human OXPHOS gene promotors, which include well-known ele-
ments found in OXPHOS genes or related genes; NRF-1; NRF-2; and
the less speciﬁc elements ERRA, SP1, MEF-2, YY1, and CREB [53–56].
Van Waveren and Moraes suggest that these factors can act
independently or synergistically, in order to allow co-regulation,
and with other factors can lead to diversity in expression [53]. An
example of this diversity and tissue-speciﬁc expression has been
described for complex IV (COX) expression in muscle [57]. In
mammals, COX may contain ubiquitous liver (L) and heart/muscle-
speciﬁc (H) isoforms for subunits COX6a and COX7a [54]. The
promotor regions of these genes lack NRF sites but contain conserved
myocyte enhancer factor 2 (MEF2) elements. Expression of MEF2A is
induced by NRF-1 over expression and, with PGC1α (a co-activator
that also binds PPARα), results in the induction of muscle-speciﬁc
gene expression of COX [57,58].
5. Mitochondrial DNA transcription and replication, regulation,
damage, and repair
The mechanism involved in the transcription and replication of
mtDNA is well documented [59–61] and, as is evident from the report
summary in Table 1, clearly involved in expression of OXPHOS
disorders. In normal tissue, mitochondrial DNA copy number varies
relative to oxidative capacity and energy needs [56]. These variations
may be markedly affected in OXPHOS deﬁciencies, and reports show
either a decreased [33–35] or increased [35] mtDNA/nDNA ratio,
assuming that nomutations in replication/transcription genes exist in
these patients. It has been proposed that mitochondrial gene
expression is regulated not only by nuclear encoded transcriptional
or post-transcriptional mechanisms, but also by the mtDNA copy
number of the cell itself [62,63]. The mechanism for this is unclear,
although several of the regulatory proteins involved in mtDNA
transcription/replication (TFAM, POLRMT, mtSSB) are co-ordinately
expressed with changes in mtDNA copy number [64,69,66]. Miranda
et al., however, demonstrate induced expression of NRF-1 and TFAM
mRNA in ρ° HeLa cells that correlated with ROS levels [50]. Increased
expression of these factors is also found in OXPHOS deﬁcient human
cells, in aged skeletal muscle [56], and in HeLa cells treated with
menadione that leads to increased superoxide formation [50]. Another
key regulator of mtDNA maintenance and copy number is Twinkle
helicase [67], although very little is knowabout its regulation. Notably,
the regulation of mitochondrial DNA polymerase, DNApolγ, appears
not to be affected bymtDNA levels or its maintenance and is expressed
at levels sufﬁcient to support variation among tissues [65,66].
Knowledge of the regulation of nucleus-to-mitochondria (ante-
rograde) signalling that controls these events is still largely lacking.
Mitochondrial transcription involves binding of mitochondrial RNA
polymerase on three possible promotor sites, in association with
TFAM and one of two transcription factor B paralogs, TFB1M and
TFB2M [60]. These transcription factors have distinct roles in vivo, and
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transcription-primed replication, while TFB1M over expression does
not affect these processes but still increases mitochondrial biogenesis
[68]. Furthermore, over expression of TFB2M induces TFB1M expres-
sion, which suggests that there is a retrograde signalling pathway that
co-ordinately expresses these transcription factors [68]. It is interest-
ing to note that the expression of these controlling factors of mtDNA
transcription also contains the NRF-recognition sites that are trans-
activated by the PGC1 family co-activators, PGC1α and PRC [58,69].
These controlling elements are thus shared between the expression of
both nuclear- and mitochondrial-encoded OXPHOS genes.
It is well-known that methylation of DNA plays an important role
in epigenetic events: DNA-methyltransferases (DNA-MTase) catalyse
the addition of a methyl group to a cytosine ring in CpG dinucleotides
leading to 5-methylcytosine, which is generally associated with
reduced gene expression. This occurs either by blocking binding of
transcription factors, binding transcription repressors, or changing
chromatin structure [70]. For the mitochondrion evidence of DNA
methylation is lacking. However, TFB1M and TFB2M are homologues
to rRNA methyltransferases and the role of TFB1M in ribosome
biogenesis is proposed [60,64,68,71]. Although methylation and other
epigenetic events play an important role in nDNA transcription
regulation and maintenance, information on the occurrence and role
of these factors in mtDNA expression and maintenance needs further
study.
Damage to mtDNA is often highlighted as a factor affecting
expression of mtDNA genes and thus contributing to secondary
consequences of OXPHOS deﬁciencies. Considering its structure,
maintenance, and close localization to sources of oxidative damage,
this maywell be a signiﬁcant factor in disease expression. Owing to its
close proximity to the site of mitochondrial ROS production and
comparatively less efﬁcient mtDNA damage repair, mtDNA is more
sensitive to oxidative damage than nDNA [72]. It has also been
demonstrated that oxidative damage is more likely to occur in the
controlling D-loop region [56,73]. The compounding factors for
oxidation of mtDNA are the close proximity of metal ions that act as
catalysts and ROS damage to OXPHOS complexes that result in
secondary ROS [72]. The lack of protective histones around themtDNA
is also suggested to contribute to the sensitivity of the mtDNA to
oxidative damage, although the presence of regulating proteins, such
as TFAM, on mtDNA may have a protective effect against ROS damage
[74,75]. It has now been established that mtDNA damage is primarily
repaired through the ATP-dependent base excision repair pathway
[76–80].
The factors regulating mtDNA replication and transcription are
thus highly diverse and tightly controlled by mitochondria–nucleus
signalling. In addition, more immediate factors such as ROS, metabolic
regulation and defensemechanisms that determine levels of oxidative
stress and possibly epigenetic factors, control expression and main-
tenance. These factors are frequently evaluated separately. Consider-
ing the diverse expression proﬁles that were reported for mtDNA in
OXPHOS deﬁciencies, as well as the regulation of the factors
controlling its expression, the interplay of all these factors need to
be evaluated to obtain a better understanding of how the mitochon-
drion responds to OXPHOS deﬁciencies.
6. Conclusion
The complex and almost unpredictable nature of disease pheno-
types associated with OXPHOS deﬁciency has been a considerable
impediment in the characterization and treatment of OXPHOS
deﬁciencies. The effect of OXPHOS deﬁciencies on mitochondrial and
nuclear DNA expression and regulation has been investigated in
several studies in an attempt to clarify the adaptive responses in
OXPHOS disease phenotypes. These include genes involved in mtDNA
maintenance, uncoupling, biogenesis, defensemechanisms, apoptosis,and metabolic regulation. A striking observation from these investiga-
tions is the great variation that exists in the differential expression of
both the nuclear andmitochondrial DNA, which prompted this review
of expression proﬁles and the mechanisms involved.
As summarized in Fig. 1, the immediate (such as ROS and ATP) and
secondary (such as Ca2+) consequences of OXPHOS deﬁciencies are
key mediators in retrograde signalling events that induce expression
of nuclear OXPHOS and other genes involved in various cellular
processes. Many of the signalling elements and promotor binding sites
that control expression of these nuclear genes have now been
identiﬁed and demonstrate that, in the case of OXPHOS and mtDNA
maintenance genes, coordinate (ROS and Ca2+ sensitive) expression
occurs. The origin and role of ROS is diverse, as its function in the
oxidation of macromolecules, including mtDNA and RNA, also
contributes to the way mtDNA transcription and replication occur.
An aspect that needs to be investigated further is the occurrence and
possible role of epigenetic events in the mitochondrion, which may,
similar to nuclear DNA, have a marked effect on the expression and
maintenance of mtDNA.
Although current data of the expression of genes involved in
energy metabolism in OXPHOS deﬁciencies exhibit diverse proﬁles
and (often) inconsistencies, it is clear that the expression of these
genes contributes to the disease expression of OXPHOS deﬁciencies. In
order to obtain an improved understanding of the intricate con-
sequences and adaptive responses in OXPHOS disorders, the expres-
sion of nuclear and mitochondrial genes needs to be evaluated
holistically, in combination with the signalling processes and
metabolites involved and in well-deﬁned disease models. Such an
investigation poses a signiﬁcant challenge, but recent developments
in systems biology technologies may soon overcome any difﬁculties
posed.
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